Treatment for asymptomatic stargardt disease patients
AssigneeAlkeus Pharmaceuticals, Inc.
InventorLeonide C. Saad
Life of this patent
Estimating the term…
Abstract
Disclosed is a method of delaying the onset of Stargardt disease symptoms in an asymptomatic Stargardt disease patient. Also disclosed is a method of delaying the onset of vision loss in an asymptomatic Stargardt disease patient. Also disclosed is a method of treating a Stargardt disease patient to delay the onset of vision loss in the Stargardt disease patient, wherein treatment is initiated prior to the patient experiencing vision loss resulting from the Stargardt disease. The methods comprise administering to the patient an effective amount of gildeuretinol acetate.
Claims31
1-14. (canceled)
A method of delaying the onset of Stargardt disease symptoms in an asymptomatic Stargardt disease patient, comprising administering to the patient an effective amount of gildeuretinol acetate.
A method of delaying the onset of vision loss in an asymptomatic Stargardt disease patient, comprising administering to the patient an effective amount of gildeuretinol acetate.
A method of treating a Stargardt disease patient to delay the onset of vision loss in the Stargardt disease patient, wherein treatment is initiated prior to the patient experiencing vision loss resulting from the Stargardt disease, comprising administering to the patient an effective amount of gildeuretinol acetate.
Dependencies are inferred from the claim text.